Page 8 - norgine-annual-report-2016

to improve the understanding of complex diseases and treatments, without compromising their
Dreux
Part of Norgine’s strength as a partner lies in
its high quality manufacturing and distribution
facilities in Hengoed, Wales and Dreux,
Hengoed
France and with its external
contract manufacturing.
Norgine has the ability to integrate and
launch new innovative products very quickly.
Manufacturing
A number of significant efficiency improvements were introduced
at Hengoed, which further contributed to a substantial increase in
its output of MOVICOL and MOVIPREP for Europe but also for
®
®
Norgine’s partners in the US, Japan and the rest of the world.
Of note, in 2016, for the second time, the Hengoed site was awarded
the RoSPA Health and Safety Award in recognition of excellence in
safety performance.
Norgine introduced new technologies in the Dreux facility in France to
support the launch of MOVICOL Ready to Take.
®
Patient centricity
Over the years, Norgine has established relationships with key opinion
leaders, professional organisations and health services to help
navigate complex systems and ensure that patients gain access
to its products.
Norgine has a long history of actively working with patient groups.
In 2016, Norgine supported 26 such organisations.
Norgine works together with patient groups to achieve common goals
whether these are to shape policies for the benefit of the patients or
7 8
independence.
Support the detection of colorectal cancer
As a leader in bowel cleansing and colonoscopy, Norgine continued to collaborate with patient
groups both pan-European and country-specific, to increase the detection of colorectal cancer
and to help improve patients’ quality of life. Colorectal cancer is the second most common
cause of cancer-related mortality in the world, with nearly 1.4 million new cases diagnosed
3
worldwide and 412,000 people in Europe. 4,5
Advance the understanding of hepatic encephalopathy
We continued to collaborate with patient groups both pan-European and country-specific to
ensure that hepatic encephalopathy is recognised as a life threatening condition and healthcare
systems report it like other critical conditions, so that patients can be managed accordingly.
In Europe 200,000 people are affected by hepatic encephalopathy and yet it remains
6
under-diagnosed and under-treated, as many patients and carers are unaware of the signs
and symptoms of the disease.
Improve diagnosis of head and neck cancer
Norgine started collaborating with patient groups to help standardise the use of sentinel lymph node
detection, in particular in the field of head and neck cancer. In current practice, patients with early
oral cancer undergo major surgery to remove the lymph nodes to evaluate if the cancer has spread.
Sentinel lymph node biopsy is a procedure to remove and examine the first nodes where cancer
cells may be present. The standardisation of sentinel lymph node biopsy is important because
70-80% of patients with head and neck cancer may receive a potentially avoidable major operation
which they did not need to identify that their lymph nodes were in fact negative. 7
Governance
In 2016, Norgine continued to operate and meet the strict regulatory requirements which govern
the pharmaceutical sector. Norgine seeks to always remain compliant with relevant laws,
regulations and the Norgine Business Code. All Norgine employees are expected to conduct
their duties according to the highest ethical and professional business standards.
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012.
Eur J Cancer 2013;49:1374-1403.
2. Colorectal Cancer Statistics, World Cancer Research Fund International, http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/
colorectal-cancer-statistics [Accessed 10 May 2017].
3. Zavoral M, et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15(47):5907-5915
4. Amodio P, Del Piccolo F, Pettenò E, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic
patients. J Hepatol. 2001;35(1):37-45.
5. Civantos FJ, et al. J Clin Oncol 2010; 28(8): 1395-1400.
6. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the
American Association for the Study of Liver Diseases. Journal of Hepatology 2014; 61(3):642-659.
7. Civantos FJ, et al. J Clin Oncol 2010; 28(8): 1395-1400.